Cytosorbents CORP (CTSO) Hedge Fund & Institutional Holdings (Q2 2026)

CTSO ranks #6067 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

52 institutions disclose a position in CTSO, but none treat it as a major bet — even CM Management, LLC, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

XTX Topco Ltd has added to its CTSO position for two straight quarters, increasing it by $1.3K to reach $20.3K today.

Avenir CORP has trimmed its CTSO position for two straight quarters, cutting it by $1.4M while still holding $1.9M.

CTSO reported a net loss of $18.2M over the trailing twelve months.

• Not yet profitable — net loss of $18.2M over the trailing twelve months
• Revenue grew 21.4% year over year
• Net income declined year over year, from -$10.2M to -$18.2M
• Operating cash flow was negative, using $12.4M in cash
• Current ratio of 2.13x — enough short-term assets to cover short-term liabilities
• Liabilities run 6.48x equity — a highly leveraged balance sheet worth noting